Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75362 | 0.86 | SLC1A1 (0.55) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| SCHEMBL5739966 | 0.86 | SLC1A1 (0.55) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| SCHEMBL6162540 | 0.86 | SLC1A1 (0.55) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL75361 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2IDO1AGXTDPP4 | |
| Hydrochloric Acid SCHEMBL32677237 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2IDO1AGXTDPP4 | |
| SCHEMBL7339183 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| SCHEMBL839832 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| SCHEMBL839078 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2DPP4DPP7DPP8 | |
| Hydrochloric Acid SCHEMBL6164874 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2IDO1AGXTDPP4 | |
| Hydrochloric Acid SCHEMBL27478280 | 0.85 | SLC1A1 (0.54) | SLC1A1ROCK2IDO1AGXTDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230106577-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-3344275-B1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | AILERON THERAPEUTICS INC (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2023-02-02 | — | — | US | disclosed |
| EP-3938051-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | Aileron Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMAN-LA ROCHE, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20140378390-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2014-12-25 | — | — | US | disclosed |
| US-8859723-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2013123267-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123266-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-08-15 | — | — | US | disclosed |
| EP-2603600-A2 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012173846-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012021876-A2 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127248-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | SLC1A1 3968/4885ROCK2 2852/4885IDO1 2064/4885 |
| US-20130210743-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | SLC1A1 3938/4885ROCK2 864/4885IDO1 1962/4885 |
| US-20230119612-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SLC1A1 3856/4885ROCK2 2913/4885IDO1 2962/4885 |
| US-20230037284-A9 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | SLC1A1 4486/4885ROCK2 456/4885IDO1 2819/4885 |
| US-20210299211-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | MDM2, TP53, TP53BP1 | SLC1A1 3968/4885ROCK2 2852/4885IDO1 2064/4885 |
| US-20230106577-A1 | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF | TP53, TP53BP1, MDM2 | SLC1A1 4806/4885ROCK2 2989/4885IDO1 4337/4885 |
| US-11091522-B2 | Peptidomimetic macrocycles and uses thereof | FLT3, BID, GRPR | SLC1A1 4654/4885ROCK2 412/4885IDO1 3458/4885 |
| US-20140378390-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | SLC1A1 3938/4885ROCK2 864/4885IDO1 1962/4885 |
| US-20220000968-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SLC1A1 3856/4885ROCK2 2913/4885IDO1 2962/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | SLC1A1 3452/4885ROCK2 2742/4885IDO1 2296/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | SLC1A1 3862/4885ROCK2 1311/4885IDO1 2964/4885 |
| US-20210363189-A1 | COMBINATION THERAPY OF PEPTIDOMIMETIC MACROCYCLES | BID, FLT3, GRPR | SLC1A1 4486/4885ROCK2 456/4885IDO1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.